Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Agenus

Sort by

Northwest Biotherapeutics and Agenus: What Are The Implications for These Companies in the Aftermath of Two Recent Cancer Vaccine Trial Failures? (NWBO, $0.38, Buy) (AGEN, $3.99, Buy)

Monday, February 27, 2017 · 12:10 pm

Read More

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Tuesday, January 3, 2017 · 10:18 am

Read More

Immuno-Oncology is Probably The Most Explosive Commercial Opportunity in All of BioPharma; My Investment Picks are Bristol-Myers Squibb (BMY, Buy, $57.14) and Agenus (AGEN, Buy, $4.28))

Friday, December 9, 2016 · 2:37 pm

Read More

Agenus: Update on Drug Development Programs (AGEN; Buy, $5.65)

Tuesday, August 2, 2016 · 9:28 am

Read More

Agenus: Its Market Leading Position in Immuno-Oncology Makes it A Compelling Investment Story (AGEN, Buy, $3.69)

Tuesday, May 3, 2016 · 12:40 pm

Read More

Agenus (AGEN: Buy, $6.61) Royalty Deal for QS-21 Adjuvant Use in Two Glaxo Vaccines

Thursday, September 10, 2015 · 8:32 am

Read More

Agenus: Its R&D Day Presentation Puts a Focus on the Great Promise of Cancer Vaccines and Checkpoint Modulators (AGEN, Buy, $6.73)

Monday, May 18, 2015 · 11:01 am

Read More

Agenus: The Collaboration with Incyte is Transformative and Creates Great Shareholder Value (AGEN, Buy, $4.99)

Friday, January 9, 2015 · 11:26 am

Read More

Agenus: Encouraging Data on Prophage, But What is the Path Forward (AGEN, Buy, $3.28)

Monday, July 14, 2014 · 1:44 pm

Read More

Agenus (AGEN, Buy, $3.73) Thoughts on the Stock and Company in the Aftermath of Trial Failure of MAGE-A3 Cancer Vaccine

Thursday, March 20, 2014 · 8:56 am

Read More

Agenus: There Has Been a Positive,Transformational Change in the Investment Thesis (AGEN, $3.67)

Thursday, February 20, 2014 · 12:28 pm

Read More

The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)

Friday, February 14, 2014 · 4:28 pm

Read More

Agenus: Encouraging Phase II Results for Prophage in Recurrent Glioblastoma (AGEN, $3.00)

Monday, December 16, 2013 · 8:40 pm

Read More

Agenus and Glaxo: Sizing Up the Potential for the RTS,S Malaria Vaccine (AGEN, $2.94)

Wednesday, October 9, 2013 · 5:43 pm

Read More

Agenus: Rebuttal To Attack By Adam Feuerstein on the Company (AGEN, Buy, $2.85)

Saturday, September 21, 2013 · 9:54 am

Read More

Agenus: Thoughts on Phase II Results for Prophage in Glioblastoma (AGEN, $2.91)

Wednesday, September 18, 2013 · 2:34 pm

Read More

Agenus: Assessing Stock Prospects in the Aftermath of MAGE A-3 Cancer Vaccine Missing Primary Endpoint in Melanoma (AGEN, $2.81)

Thursday, September 5, 2013 · 3:40 pm

Read More

Agenus: Upcoming Clinical Trial Results for the MAGE A-3 Cancer Vaccine Will Have a Major Impact on the Stock (AGEN, $3.42)

Wednesday, August 21, 2013 · 1:15 pm

Read More

Agenus: Key Clinical Events are Imminent (AGEN, $3.91)

Wednesday, July 17, 2013 · 3:46 pm

Read More

There are 19 reports on file.

« Back to Company Reports Index